The decade-long journey for a promising Duchenne muscular dystrophy treatment has reached a devastating conclusion, as PTC Therapeutics has officially withdrawn its application for Translarna from the U.S. market, marking the end of a contentious and ultimately unsuccessful bid for regulatory
As Costa Rican health officials monitor the nation's respiratory illness landscape, data from the Ministry of Health reveals a clear and pressing public health concern: Influenza A has firmly established itself as the most dominant circulating virus, outpacing both rhinovirus and COVID-19. In the
The loss of an adult tooth has long been considered a permanent event, a problem addressed only by synthetic replacements like dentures or implants that, while functional, are not a true biological restoration. However, a revolutionary wave of research emerging from Japan is challenging this
BioMarin Pharmaceutical is currently navigating a complex financial landscape as it prepares to release its financial results for the fourth quarter of 2025, presenting a puzzling scenario for the investment community. The prevailing consensus suggests a significant year-over-year decline in the
AstraZeneca has strategically positioned its formidable oncology portfolio as the primary engine for significant growth this year, banking on the robust and expanding demand for its cancer-fighting medicines to navigate a complex global landscape. Buoyed by a strong financial performance in 2025,
The landscape of cancer treatment is continually being reshaped by leaders who can seamlessly bridge the gap between groundbreaking research and compassionate patient care. In a significant move to further this evolution, NYU Langone Health has announced the appointment of Dr. Daniel R. Gomez, a
